Renchi Yang
Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College. · Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences · Chinese Academy of Medical Science and Blood Disease Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Renchi Yang as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:40 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07684898 · Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.Hangzhou Gensciences Biopharmaceutical Co., Ltd. · active not recruiting · Severe Hemophilia A · study chair
- Ph3NCT07663903 · Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand TreatmentHangzhou Gensciences Biopharmaceutical Co., Ltd. · active not recruiting · Severe Hemophilia A · study chair
- Ph3NCT07545395 · Safety of KN057 Prophylaxis in Patients With Haemophilia A or BSuzhou Alphamab Co., Ltd. · recruiting · Hemophilia A or B · principal investigator
- Ph3NCT06569108 · Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without InhibitorsSuzhou Alphamab Co., Ltd. · active not recruiting · Hemophilia A Without Inhibitor, Hemophilia B Without Inhibitor · principal investigator
- Ph3NCT06312475 · Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With InhibitorsSuzhou Alphamab Co., Ltd. · active not recruiting · Hemophilia A With Inhibitor, Hemophilia B With Inhibitor · principal investigator
- Ph3NCT06142552 · Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion ProteinHangzhou Gensciences Biopharmaceutical Co., Ltd. · completed · Severe Hemophilia A · study chair
- Ph4NCT05888870 · ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer InhibitorInstitute of Hematology & Blood Diseases Hospital, China · recruiting · Hemophilia A With Inhibitor · principal investigator
- Ph1NCT05651061 · A Phase I of SS109 in Hemophilia A or and B With InhibitorsHangzhou Gensciences Biopharmaceutical Co., Ltd. · completed · Hemophilia A With Inhibitor, Hemophilia B With Inhibitor, Factor VII Deficiency · principal investigator
- Ph2NCT05421429 · KN057 Multiple Dose Study in Moderately Severe to Severe HemophiliaSuzhou Alphamab Co., Ltd. · completed · Hemophilia · principal investigator
- Ph2NCT05265286 · A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for InjectionHangzhou Gensciences Biopharmaceutical Co., Ltd. · completed · Severe Hemophilia A · principal investigator
- Ph3NCT05029635 · Phase III Study on HMPL-523 for Treatment of ITPHutchmed · completed · Primary Immune Thrombocytopenia (ITP) · principal investigator
- Ph1NCT04864743 · A Study to Evaluate the Pharmacokinetics,Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for InjectionHangzhou Gensciences Biopharmaceutical Co., Ltd. · completed · Severe Hemophilia A · principal investigator
- Ph3NCT04845399 · Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia AZhengzhou Gensciences Inc · completed · Hemophilia A · principal investigator
- Ph3NCT04456387 · An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.Zhengzhou Gensciences Inc · completed · Hemophilia A · principal investigator
- Ph2/Ph3NCT04428255 · A Clinical Study on the Efficacy and Safety of HBM9161 in Patients With ITPHarbour BioMed (Guangzhou) Co. Ltd. · completed · Primary Immune Thrombocytopenic Purpura · principal investigator
- Ph4NCT03947567 · Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia A Patients.Sinocelltech Ltd. · unknown · Hemophilia A · principal investigator
- Ph3NCT03815318 · Evaluation of SCT800 in Prophylaxis Therapy on Previous Treated Patients With Severe Hemophilia ASinocelltech Ltd. · completed · Hemophilia A · principal investigator
- N/ANCT03747653 · A Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for InjectionKaifeng Pharmaceutical (Group) Co., Ltd. · unknown · Hemophilia A · principal investigator
- N/ANCT01719692 · Low-dose Rituximab Regimens in Chinese Adult Patients With Immune ThrombocytopeniaInstitute of Hematology & Blood Diseases Hospital, China · completed · Immune Thrombocytopenic Purpura · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:40 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:40 UTC. The ranking covers the 200 most relevant of 453 PubMed records, and a shared surname and initials can bring in a namesake. All 453 on PubMed
- Fremanezumab for the Preventive Treatment of Chronic Migraine.N Engl J Med · 2017534 citationsRCR 24.1
- 406 citationsRCR 24.7
- 371 citationsRCR 20.9
- 294 citationsRCR 18.6
- Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes.Diabetes Care · 2005257 citationsRCR 6.5
- FGF21-Sirtuin 3 Axis Confers the Protective Effects of Exercise Against Diabetic Cardiomyopathy by Governing Mitochondrial Integrity.Circulation · 2022232 citationsRCR 18.4
- 208 citationsRCR 20.3
- 146 citationsRCR 9.0
- Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer.Cancer Res · 2023146 citationsRCR 11.7
- 145 citationsRCR 12.1